SPOTLIGHT: Baxter: No big legal troubles from heparin


Baxter International said it does not expect its high-profile recall of the blood thinner heparin to trigger big legal troubles despite its links to adverse reactions and patient deaths. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?